Target intelligence / Profile preview

Phospholipase A and acyltransferase 2 (PLAAT2)

Target
PLAAT2
Molecular classification
Enzyme, Phospholipase, Acyltransferase, Tumor suppressor protein
01

Overview

Phospholipase A and acyltransferase 2 (PLAAT2) is a bifunctional enzyme with both phospholipase and acyltransferase activity, catalyzing the hydrolysis of fatty acids from phospholipids (particularly at sn-1 and sn-2 positions), as well as transferring acyl groups between lipid molecules. PLAAT2 is calcium-independent and can function as a tumor suppressor, regulating cell membrane lipid composition and influencing cell proliferation and survival. It has been implicated in cancer, Poland syndrome, and cystinuria. As a member of the HRASLS family, PLAAT2’s dual enzymatic activities allow it to play a role in lipid metabolism, membrane remodeling, and potentially in cell signaling and apoptosis.

Other names
HRASLS2FLJ20556PLAAT-2HRAS-like suppressor 2phospholipase A/acyltransferase-2PLA1/2-2
02

Mechanism of action

For hypothetical drugs targeting PLAAT2, mechanisms would include inhibition or modulation of its phospholipase or acyltransferase activities, potentially affecting lipid metabolism or phospholipid-mediated signaling pathways.

03

Biological functions

Hydrolysis of phospholipids (phospholipase A1 and A2 activity, acting on sn-1 and sn-2 positions)Acyltransferase activity (O-acyl and N-acyl transfer reactions)Regulation of lipid metabolism and homeostasisTumor suppression
04

Disease associations

Cancer (including tumor suppression)Associated with Poland syndrome and cystinuria
05

Safety considerations

There are no well-documented safety concerns or therapeutic challenges specific to PLAAT2 as a drug target.Potential concerns, if antagonized, might include lipid metabolism disruption, membrane homeostasis issues, or unintended effects on cell proliferation and apoptosis.
06

Biomarkers

PLAAT2 is described as a tumor suppressor, so decreased expression or loss-of-function mutations may serve as biomarkers in cancersNo widely accepted biomarkers in the context of treatment selection or efficacy monitoring.

Beyond the preview

Go deeper on Phospholipase A and acyltransferase 2 (PLAAT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phospholipase A and acyltransferase 2 (PLAAT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call